Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has n...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bugaut, Hélène, Bruchard, Mélanie, Berger, Hélène, Derangère, Valentin, Odoul, Ludivine, Euvrard, Romain, Ladoire, Sylvain, Chalmin, Fanny, Végran, Frédérique, Rébé, Cédric, Apetoh, Lionel, Ghiringhelli, François, Mignot, Grégoire
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3676388/
https://ncbi.nlm.nih.gov/pubmed/23762310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0065181
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak